Seroquel- Agitation associated with Dementia

Study identifier:5077US/0046

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multicenter, double-blind, randomized, comparison of the efficacy and safety of Quetiapine Fumarate (SEROQUEL) and placebo in the treatment of agitation associated with dementia.

Medical condition

Alzheimer's disease

Phase

Phase 3

Healthy volunteers

No

Study drug

Quetiapine Fumarate, Placebo

Sex

All

Actual Enrollment

333

Study type

Interventional

Age

55 Years +

Date

Study Start Date: 01 Sept 2002
Primary Completion Date: 01 Nov 2003
Study Completion Date: 01 Nov 2003

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria